CymaBay Therapeutics, Inc.
http://www.cymabay.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CymaBay Therapeutics, Inc.
Zydus Looks To Revlimid Opportunity, Pivots To Multivariant COVID-19 Vaccine
Zydus is looking to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa. It is also pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response.
Zydus Pivots To Multivariant COVID-19 Vaccine, Looks To Revlimid Opportunity
Zydus is pivoting to a multivariant version of its plasmid DNA vaccine against COVID-19, ZyCoV-D, after the original didn’t receive an encouraging response. It also looks to launch a Revlimid generic in the second wave while an opportunity might soon emerge from Takeda’s Pentasa.
Dr Reddy’s Pressing On In Russia, China Approvals Add Spark
Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?
Dr Reddy’s Pressing On In Russia, China Approvals Add Spark
Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Metabolex, Inc.
- Transplantation Technology, Inc.
- Transtech Corporation
- Transtech Medical, Inc.